Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon

被引：0
|
作者：
Schuette, W. [1 ]
Thomas, M. [2 ]
Eberhardt, W. [3 ]
Zirrgiebel, U. [4 ]
Radke, S. [5 ]
Dietel, M. [6 ]
机构：
[1] Krankenhaus Martha Maria, Halle, Saale, Germany
[2] Univ Klinikum, Thoraxklin, Heidelberg, Germany
[3] Univ Klinikum, Med Onkol, Essen, Germany
[4] iOMEDICO AG, Freiburg, Germany
[5] AstraZeneca GmbH, Wedel, Germany
[6] Humboldt Univ, Pathol Inst, D-10099 Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0341
引用
收藏
页码：120 / 120
页数：1
相关论文
共 41 条
  • [21] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
  • [22] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [23] Effect of Sample Type and Turnaround Time (TAT) on the Feasibility of Non-Small Cell Lung Cancer (NSCLC) Epidermal Growth Factor Receptor (EGFR) Mutation Testing in Routine Clinical Practice: Results From the Spanish REASON Study
    Gracia, M.
    Majem, M.
    Martinez Aguillo, M. T.
    Martinez Banaclocha, N.
    Provencio, M.
    Arriola, E.
    Codes, M.
    Artal, A.
    Cajal, R.
    Massuti Sureda, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S255 - S255
  • [24] Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.
    van der Wekken, Anthonie J.
    Kuiper, Justine L.
    Heideman, Danielle A. M.
    Schuuring, Ed
    Timens, Wim
    Thunnissen, Erik
    Groen, Harry J. M.
    Smit, Egbert F.
    CANCER RESEARCH, 2013, 73 (08)
  • [25] CLINICAL IMPACT OF PRESENCE AND TYPE OF KRAS MUTATION IN A POPULATION OF EGFR WILD TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) TREATED WITH PLATINUM-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS
    Metro, G.
    Duranti, S.
    De Angelis, V.
    Chiari, R.
    Bennati, C.
    Curra, M. F.
    Giannarelli, D.
    Ludovini, V.
    Minotti, V.
    Crino, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 427 - 427
  • [26] Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patient's qualification for targeted therapy have an impact on time to obtain genetic results?
    Lewandowska, Marzena Anna
    Jozwicki, Wojciech
    Starzynski, Jaroslaw
    Kowalewski, Janusz
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 9 (04) : 443 - 451
  • [27] Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
    Ciardiello, D.
    Napolitano, S.
    De Falco, V.
    Martini, G.
    Martinelli, E.
    Della Corte, C.
    Esposito, L.
    Famiglietti, V.
    Di Liello, A.
    Avallone, A.
    Cardone, C.
    De Stefano, A.
    Montesarchio, V.
    Zampino, M.
    Fazio, N.
    Del Tufo, S.
    Di Maio, M.
    De Vita, F.
    Altucci, L.
    Marrone, F.
    Ciardiello, F.
    Troiani, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S171 - S172
  • [28] Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
    Napolitano, Stefania
    Ciardiello, Davide
    De Falco, Vincenzo
    Martini, Giulia
    Martinelli, Erika
    Della Corte, Carminia Maria
    Esposito, Lucia
    Famiglietti, Vincenzo
    Di Liello, Alessandra
    Avallone, Antonio
    Cardone, Claudia
    De Stefano, Alfonso
    Montesarchio, Vincenzo
    Zampino, Maria Giulia
    Fazio, Nicola
    Di Maio, Massimo
    Del Tufo, Sara
    De Vita, Ferdinando
    Altucci, Lucia
    Marrone, Francesca
    Ciardiello, Fortunato
    Troiani, Teresa
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (08) : 1520 - 1528
  • [29] Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
    Andrew Rowland
    Mafalda M Dias
    Michael D Wiese
    Ganessan Kichenadasse
    Ross A McKinnon
    Christos S Karapetis
    Michael J Sorich
    British Journal of Cancer, 2015, 113 : 1635 - 1635
  • [30] Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
    Rowland, Andrew
    Dias, Mafalda M.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Karapetis, Christos S.
    Sorich, Michael J.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1635 - 1635
12345